About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2011 (2011), Article ID 868095, 11 pages
http://dx.doi.org/10.1155/2011/868095
Research Article

Identification of Four Potential Epigenetic Modulators from the NCI Structural Diversity Library Using a Cell-Based Assay

1Department of Pharmacology and Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA
2Molecular Targets Laboratory, Center for SAIC-Frederick, National Cancer Institute, Frederick, MD 21702, USA
3Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute, Boulevard, Dallas, TX 75390, USA

Received 29 July 2010; Accepted 7 October 2010

Academic Editor: Minoru Yoshida

Copyright © 2011 Anne M. Best et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Jones and S. B. Baylin, “The epigenomics of cancer,” Cell, vol. 128, no. 4, pp. 683–692, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Fucito, C. Lucchetti, A. Giordano, and G. Romano, “Genetic and epigenetic alterations in breast cancer: what are the perspectives for clinical practice?” International Journal of Biochemistry and Cell Biology, vol. 40, no. 4, pp. 565–575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Huang, E. Greene, T. M. Stewart et al., “Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 19, pp. 8023–8028, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Santos-Rosa and C. Caldas, “Chromatin modifier enzymes, the histone code and cancer,” European Journal of Cancer, vol. 41, no. 16, pp. 2381–2402, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Candelaria, D. Gallardo-Rincón, C. Arce et al., “A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors,” Annals of Oncology, vol. 18, no. 9, pp. 1529–1538, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Grant, C. Easley, and P. Kirkpatrick, “Vorinostat,” Nature Reviews Drug Discovery, vol. 6, no. 1, pp. 21–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. Q. C. Ryan, D. Headlee, M. Acharya et al., “Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma,” Journal of Clinical Oncology, vol. 23, no. 17, pp. 3912–3922, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. O. Khan and N. B. La Thangue, “Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas,” Nature Clinical Practice Oncology, vol. 5, no. 12, pp. 714–726, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. D. M. Vigushin and R. C. Coombes, “Histone deacetylase inhibitors in cancer treatment,” Anti-Cancer Drugs, vol. 13, no. 1, pp. 1–13, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Nakajima, Y. B. Kim, H. Terano, M. Yoshida, and S. Horinouchi, “FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor,” Experimental Cell Research, vol. 241, no. 1, pp. 126–133, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. V. M. Richon, Y. Webb, R. Merger et al., “Second generation hybrid polar compounds are potent inducers of transformed cell differentiation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 12, pp. 5705–5708, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. O. D. Lau, T. K. Kundu, R. E. Soccio et al., “HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF,” Molecular Cell, vol. 5, no. 3, pp. 589–595, 2000. View at Scopus
  13. A. Bedalov, T. Gatbonton, W. P. Irvine, D. E. Gottschling, and J. A. Simon, “Identification of a small molecule inhibitor of Sir2p,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 26, pp. 15113–15118, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. C. M. Grozinger, E. D. Chao, H. E. Blackwell, D. Moazed, and S. L. Schreiber, “Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening,” Journal of Biological Chemistry, vol. 276, no. 42, pp. 38837–38843, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Kubicek, R. J. O'Sullivan, E. M. August et al., “Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase,” Molecular Cell, vol. 25, no. 3, pp. 473–481, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. M. Quinn, A. Allali-Hassani, M. Vedadi, and A. Simeonov, “A chemiluminescence-based method for identification of histone lysine methyltransferase inhibitors,” Molecular BioSystems, vol. 6, no. 5, pp. 782–788, 2010. View at Publisher · View at Google Scholar
  17. A. Dhayalan, E. Dimitrova, P. Rathert, and A. Jeltsch, “A continuous protein methyltransferase (G9a) assay for enzyme activity measurement and inhibitor screening,” Journal of Biomolecular Screening, vol. 14, no. 9, pp. 1129–1133, 2009.
  18. M. Yoshida, M. Kijima, M. Akita, and T. Beppu, “Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A,” Journal of Biological Chemistry, vol. 265, no. 28, pp. 17174–17179, 1990. View at Scopus
  19. S. J. Haggarty, K. M. Koeller, J. C. Wong, R. A. Butcher, and S. L. Schreiber, “Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays,” Chemistry and Biology, vol. 10, no. 5, pp. 383–396, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. S. J. Haggarty, K. M. Koeller, J. C. Wong, C. M. Grozinger, and S. L. Schreiber, “Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 8, pp. 4389–4394, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. S. W. Remiszewski, L. C. Sambucetti, K. W. Bair et al., “N-Hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activitydiscovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl] amino]methyl]-phenyl]-2-propenamide (NVP-LAQ824),” Journal of Medicinal Chemistry, vol. 46, no. 21, pp. 4609–4624, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Tan, S. Cang, Y. Ma, R. L. Petrillo, and D. Liu, “Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents,” Journal of Hematology and Oncology, vol. 3, article 5, 2010. View at Publisher · View at Google Scholar
  23. E. Kaminskas, A. T. Farrell, Y.-C. Wang, R. Sridhara, and R. Pazdur, “FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension,” Oncologist, vol. 10, no. 3, pp. 176–182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. B. S. Mann, J. R. Johnson, M. H. Cohen, R. Justice, and R. Pazdur, “FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma,” Oncologist, vol. 12, no. 10, pp. 1247–1252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. D. Gore, C. Jones, and P. Kirkpatrick, “Decitabine,” Nature Reviews Drug Discovery, vol. 5, no. 11, pp. 891–892, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Grant, F. Rahman, R. Piekarz et al., “Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors,” Expert Review of Anticancer Therapy, vol. 10, no. 7, pp. 997–1008, 2010. View at Publisher · View at Google Scholar
  27. E. D. Martinez, A. B. Dull, J. A. Beutler, and G. L. Hager, “High-content fluorescence-based screening for epigenetic modulators,” Methods in Enzymology, vol. 414, pp. 21–36, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. E. D. Martinez and G. L. Hager, “Development of assays for nuclear receptor modulators using fluorescently tagged proteins,” Methods in Enzymology, vol. 414, pp. 37–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. R. L. Johnson, W. Huang, A. Jadhav, C. P. Austin, J. Inglese, and E. D. Martinez, “A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression,” Analytical Biochemistry, vol. 375, no. 2, pp. 237–248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. U. M. Hanumegowda, V. C. Dhulipala, and C. S. Reddy, “Mechanism of secalonic acid D-induced inhibition of transcription factor binding to cyclic AMP response element in the developing murine palate,” Toxicological Sciences, vol. 70, no. 1, pp. 55–62, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Mottet and V. Castronovo, “Histone deacetylases: target enzymes for cancer therapy,” Clinical and Experimental Metastasis, vol. 25, no. 2, pp. 183–189, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Szyf, “Epigenetics, DNA methylation, and chromatin modifying drugs,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 243–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. F. Gazdar, B. Gao, and J. D. Minna, “Lung cancer cell lines: useless artifacts or invaluable tools for medical science?” Lung Cancer, vol. 68, no. 3, pp. 309–318, 2010. View at Publisher · View at Google Scholar
  34. Y.-G. He, E. Mayhew, J. Mellon, and J. Y. Niederkorn, “Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells,” Investigative Ophthalmology and Visual Science, vol. 45, no. 12, pp. 4240–4246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. S. B. Hake and C. D. Allis, “Histone H3 variants and their potential role in indexing mammalian genomes: the “H3 barcode hypothesis”,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 17, pp. 6428–6435, 2006. View at Publisher · View at Google Scholar · View at Scopus